ArticleTranslational lung cancer research2022

Prospective evaluation of immunological, molecular-genetic, image-based and microbial analyses to characterize tumor response and control in patients with unresectable stage III NSCLC treated with concurrent chemoradiotherapy followed by consolidation therapy with durvalumab (PRECISION): protocol for a prospective longitudinal biomarker study.

Lukas Käsmann et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.